Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesPrecipio Inc

Precipio Inc

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
24.58 USD 0.93 ( 3.93%)
Last update at 2026-11-11T20:46:00Z
VOLUME
27827
Market Cap
48.62M

Momentum Score

…

Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
22.76
Low
25.34
High
52 Week Price Range
16.00
Low
33.63
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
23.65
Dividend Yield
-
Revenue TTM
27.20M
Revenue Per Share
15.60
Gross Profit TTM
12.00M
Debt / Equity
0.25
ROE
-8.98%
Net Debt
-2.39M
ROCE
-1.65%
Diluted EPS TTM
-0.62

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -0.36M -4.29M -5.85M -12.18M -8.52M
Minority interest - - -0.01M -0.03M -0.01M
Net income -0.36M -4.29M -5.85M -12.20M -8.55M
Selling general administrative - 11.68M 13.54M - -
Selling and marketing expenses - 0.10M 0.10M - -
Gross profit 10.71M 7.56M 6.02M 2.51M 2.39M
Reconciled depreciation 1.75M 1.51M 1.52M 1.52M 1.44M
Ebit -0.29M -4.22M -5.83M -12.80M -9.61M
Ebitda 1.46M -2.70M -4.53M -11.28M -8.17M
Depreciation and amortization 1.75M 1.51M 1.31M 1.52M 1.44M
Operating income -1.20M -4.22M -7.62M -12.80M -9.61M
Other operating expenses 25.25M 20.18M 22.82M 22.21M 18.46M
Interest expense 0.07M 0.07M 0.02M 0.01M 0.02M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Net interest income -0.07M -0.07M -0.02M -0.01M -0.02M
Income tax expense - - 1.35M 0.03M 0.03M
Total revenue 24.05M 15.96M 15.20M 9.41M 8.85M
Total operating expenses 11.91M 11.78M 13.64M 15.31M 12.01M
Cost of revenue 13.34M 8.41M 9.18M 6.90M 6.46M
Total other income expense net 0.84M -0.07M 1.77M 0.62M 1.10M
Net income from continuing ops -0.36M -4.29M -9.06M -12.18M -8.52M
Net income applicable to common shares - - - - -8.53M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 21.32M 17.00M 18.10M 21.50M 30.44M
Intangible assets 10.92M 11.87M 12.82M 13.77M 14.72M
Other current assets -2.92M 0.54M 0.49M 0.52M 0.55M
Total liab 6.76M 4.90M 3.67M 5.14M 5.83M
Total stockholder equity 14.56M 12.09M 14.43M 16.30M 24.56M
Other current liab 1.97M 2.63M 1.82M 1.58M 1.92M
Common stock 0.02M 0.01M 0.01M 0.23M 0.23M
Capital stock 0.02M 0.01M 0.01M 0.23M 0.23M
Retained earnings -102.80M -102.44M -98.15M -92.30M -80.09M
Other liab - - - - 0.61M
Other assets - 0.00M 0.00M - 0.18M
Cash 6.04M 1.39M 1.50M 3.44M 11.67M
Total current liabilities 3.75M 4.27M 3.14M 4.36M 4.21M
Current deferred revenue - 0.23M 0.11M 0.12M 0.02M
Net debt -2.39M -0.14M -0.39M -2.05M -10.24M
Short term debt 0.65M 0.62M 0.58M 0.62M 0.41M
Short long term debt 0.03M 0.30M 0.23M 0.26M 0.03M
Short long term debt total 3.65M 1.25M 1.12M 1.39M 1.43M
Other stockholder equity 117.35M 114.52M 112.56M 108.37M 104.43M
Property plant equipment - - - - 2.06M
Total current assets 6.04M 3.45M 3.68M 5.71M 13.48M
Net tangible assets - - - - 9.85M
Net receivables 1.98M 0.80M 1.30M 1.04M 0.70M
Long term debt 0.05M 0.08M 0.11M 0.13M 0.16M
Inventory 0.94M 0.72M 0.38M 0.71M 0.56M
Accounts payable 1.13M 0.62M 0.62M 2.04M 1.86M
Accumulated other comprehensive income - - 0.00M - -
Non currrent assets other 0.07M 0.04M 0.08M 0.13M 0.18M
Non current assets total 15.28M 13.54M 14.42M 15.79M 16.96M
Capital lease obligations 3.58M 0.88M 0.78M 1.00M 1.24M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.22M -0.13M -0.28M -0.68M
Change to liabilities - - - - 0.11M
Total cashflows from investing activities -0.33M -0.22M -0.13M - -0.68M
Net borrowings -0.48M -0.41M -0.50M - -0.17M
Total cash from financing activities 0.90M -0.33M 1.74M -0.23M 16.27M
Change to operating activities - - - - -0.62M
Net income -0.36M -4.29M -5.85M -12.18M -8.52M
Change in cash 1.26M -0.11M -1.94M -8.22M 9.01M
Begin period cash flow 1.39M 1.50M 3.44M 11.67M 2.66M
End period cash flow 2.65M 1.39M 1.50M 3.44M 11.67M
Total cash from operating activities 0.69M 0.44M -3.56M -7.72M -6.58M
Issuance of capital stock 0.00M 0.08M 2.25M 0.13M 16.21M
Depreciation 1.56M 1.51M 1.52M 1.52M 1.44M
Change to inventory -0.21M -0.34M 0.32M -0.14M -0.21M
Change to account receivables -1.36M 0.44M -0.48M -0.74M 0.33M
Other cashflows from financing activities 0.90M -0.41M -0.13M 0.01M 0.27M
Change to netincome - - - - 0.90M
Capital expenditures 0.33M 0.22M 0.13M 0.28M 0.68M
Change in working capital -2.17M 1.27M 0.61M -0.64M -0.40M
Stock based compensation 1.21M 1.88M 1.74M 3.80M 1.88M
Other non cash items 0.44M 0.07M -1.56M -0.22M 0.23M
Free cash flow 0.36M 0.22M -3.69M -8.00M -7.26M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
PRPO
Precipio Inc		 0.93
3.93%		 24.58 - 15.43 1.79 3.29 1.81 75.19
TMO
Thermo Fisher Scientific Inc		 -0.49
0.07%		 717.71 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 -0.80
0.34%		 235.31 29.09 28.01 5.67 3.20 6.00 19.09
WUXIF
WuXi AppTec Co. Ltd		 -
-%		 25.84 22.29 17.95 1.53 5.98 8.39 14.30
WUXAY
WuXi AppTec Co. Ltd		 -0.50
1.94%		 25.10 23.28 18.73 1.51 6.24 8.39 14.30

Profile*

Precipio Inc

Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.

4 Science Park, New Haven, CT, United States, 06511

203 787 7888

https://www.precipiodx.com

61

Name Title Year Born
Mr. Ahmed Zaki Sabet Chief Operating Officer 1987
Mr. Ilan Danieli Founder, Pres, CEO & Director 1972
Dr. Ayman Mohamed M.D. Chief Technology Officer 1985
Mr. Matthew Gage Interim Chief Financial Officer 1967
Ms. Miri Chiko-Radomski Chief Legal Counsel & People Officer NA
Mr. Keith Meadors Sr. VP of Products Division NA
Mr. Ilan Danieli Founder, President, CEO & Director 1972
Dr. Ayman A. Mohamed M.D. Chief Technology Officer 1985
Mr. Matthew Gage Chief Financial Officer 1967
Mr. Ahmed Zaki Sabet Chief Operating Officer 1985

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…